Genetic polymorphisms and protein expression of NRF2 and sulfiredoxin predict survival outcomes in breast cancer

Cancer Research

Volumn 72, Issue 21, 2012, Pages 5537-5546

  Hartikainen, Jaana M ^a,c,d   Tengström, Maria ^b,e   Kosma, Veli Matti ^a,c,d   Kinnula, Vuokko L ^f   Mannermaa, Arto ^a,c,d   Soini, Ylermi ^a,c,d  

^a Department of Pathology and Forensic Medicine ^*  (Finland)

^b Institute of Clinical Medicine   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d Imaging Center Clinical Pathology   (Finland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

^f UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXIREDOXIN; REACTIVE OXYGEN METABOLITE; SULFIREDOXIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR MECHANICS; NRF2 GENE; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SRXN1 GENE; SURVIVAL PREDICTION; TRANSCRIPTION INITIATION;

BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; NF-E2-RELATED FACTOR 2; OXIDOREDUCTASES ACTING ON SULFUR GROUP DONORS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; TRANSCRIPTOME;

EID: 84868249403     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1474     Document Type: Article

References (45)

1. Itoh K, Mimura J, Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal 2010;13: 1665-78.
2. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual rolesof Nrf2 in cancer. Pharmacol Res 2008;58:262-70.
3. Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, Kensler TW, et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest2004;114:1248-59.
4. Sugimoto H, Okada K, Shoda J, Warabi E, Ishige K, Ueda T, et al. Deletion of nuclearfactor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice. Am J Physiol Gas-trointest Liver Physiol 2010;298:G283-94.
5. Hu L, Miao W, Loignon M, Kandouz M, Batist G. Putative chemo-preventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies. Cancer Chemother Pharmacol 2010;66:467-74.
6. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY, et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 2010;220:446-51.
7. Hayes JD, Mc Mahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009;34:176-88.
8. Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, et al. RNAi-mediated silencing of nuclearfactorerythroid-2-relatedfactor2 geneexpression in non-small cell lung cancerinhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 2008;68:7975-84.
9. Cox AG, Winterbourn CC, Hampton MB. Mitochondrial peroxiredoxin involvement in antioxidant defense and redox signaling. Biochem J 2009;425:313-25.
10. Rhee SG, Yang KS, Kang SW, Woo HA, Chang TS. Con-trolled elimination of intracellular H(2)O(2): regulation of per-oxiredoxin, catalase, and glutathione peroxidase via post-translational modification. Antioxid Redox Signal 2005;7: 619-26.
11. Woo HA, Jeong W, Chang TS, Park KJ, Park SJ, Yang JS, et al. Reduction of cysteine sulfinic acid by sulfiredoxin is specific to 2-cys peroxiredoxins. J Biol Chem 2005;280:3125-8.
12. Findlay VJ, Tapiero H, Townsend DM. Sulfiredoxin: a potential ther-apeutic agent? Biomed Pharmacother 2005;59:374-9.
13. Lei K, Townsend DM, Tew KD.Proteincyste inesulfinic acid reductase (sulfiredoxin) as a regulator of cell proliferation and drug response. Oncogene 2008;27:4877-87.
14. Soriano FX, Baxter P, Murray LM, Sporn MB, Gillingwater TH, Hard-ingham GE.Transcriptionalregulationofthe AP-1 and Nrf2 target gene sulfiredoxin. Mol Cells 2009;27:279-82.
15. Singh A, Ling G, Suhasini AN, Zhang P, Yamamoto M, Navas-Acien A, et al. Nrf2-dependent sulfiredoxin-1 expression protects against cig-arette smoke-induced oxidative stress in lungs. Free Radic Biol Med 2009;46:376-86.
16. Wei Q, Jiang H, Matthews CP, Colburn NH. Sulfiredoxin is an AP-1 target gene that is required for transformation and shows elevated expression in human skin malignancies. Proc Natl Acad Sci USA 2008; 105:19738-43.
17. Tavassoli FA, Devilee P. Tumours of the breast and female genital organs. World Health Organization classification of tumours. Lyon, France: IARC Press; 2003.
18. Hartikainen JM, Tuhkanen H, Kataja V, Dunning AM, Antoniou A, Smith P, et al. An autosome-wide scan for linkage disequilibrium-based association in sporadic breast cancer cases in Eastern Finland: three candidate regions found. Cancer Epidemiol Biomarkers Prev 2005;14: 75-80.
19. Pellikainen MJ, Pekola TT, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen M, et al. p21WAF1 expression in invasive breast cancerand its association with p53, AP-2, cell proliferation, and prognosis. J Clin Pathol 2003;56:214-20.
20. Vandenplas S, Wiid J, Grobler-Rabie A, Brebner K, Ricketts M, Wallis G, et al. Blot hybridization of genomic DNA. J Med Genet 1984;21: 164-72.
21. Kauppinen JM, Kosma V-M, Soini Y, Sironen R, Nissinen M, Nykopp TK, et al. ST14 genevariant and decreased matriptase protein expres-sion predict poor breast cancer survival. Cancer Epidemiology Bio-markers Prev 2010;19:2133-42.
22. Available from: http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/ hapmap3r2-B36/. [cited 2010 Feb 24 and 2010 Nov 8.]
23. Yamamoto T, Yoh K, Kobayashi A, Ishii Y, Kure S, Koyama A, et al. Identification of polymorphisms in the promoter region of the human NRF2 gene. Biochem Biophys Res Commun 2004;321:72-9.
24. Marzec JM, Christie JD, Reddy SP, Jedlicka AE, Vuong H, Lanken PN, et al. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J 2007;21: 2237-46.
25. Voutilainen K, Anttila M, Sillanpaa S, Tammi R, Tammi M, Saarikoski S, et al. Versican in epithelial ovarian cancer: relation to hyalyronan, clinicopathological factors and prognosis. Int J Cancer 2003;107: 359-64.
26. Karihtala P, Soini Y. Reactive oxygen species and antioxidant mechan-isms in human tissues and their relation to malignancies. APMIS 2007;115:81-103.
27. Yuan H-Y, Chiou J-J, Tseng W-H, Liu C-H, Liu C-K, Lin Y-J, et al. FASTSNP: an always up-to-date and extendable service for SNP func-tion analysis and prioritization. Nucleic Acids Res 2006;34:W635-41.
28. Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sani-setty A, Grammatikos AP, et al. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res 2011;71:5081-9.
29. Hong CC, Ambrosone CB, Ahn J, Choi JY, Mc Cullough ML, Stevens VL, et al. Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmeno-pausal breast cancer. Cancer Epidemiol Biomarkers Prev 2007;16: 1784-94.
30. Bouligand J, Cabaret O, Canonico M, Verstuyft C, Dubert L, Becque-mont L, et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembo-ism in postmenopausal women. Clin Pharmacol Ther2011;89:60-4.
31. Masuko H, Sakamoto T, Kaneko Y, Iijima H, Naito T, Noguchi E, et al. An interaction between Nrf2 polymorphisms and smoking status affects annual decline in FEV1: a longitudinal retrospective cohort study. BMC Med Genet 2011;12:97.
32. Cho HY, Jedlicka AE, Reddy SP, Zhang LY, Kensler TW, Kleeberger SR. Linkage analysis of susceptibility to hyperoxia. Nrf2 is a candidate gene. Am J Respir Cell Mol Biol 2002;26:42-51.
33. Valavanidis A, Vlachogianni T, fiotakis K. Tobacco smoke: involvement of reactive oxygen species and stable free radicals in mechanisms of oxidative damage, carcinogenesis and synergistic effects with other respirable particles. Int J Environ Res Public Health 2009;6:445-62.
34. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, et al. Nrf2 gene polymorphism and gastric carcinogenesis. Hepato-gastroenterology 2008;55:7504.
35. Sepulveda AR, Graham DY. Role of Helicobacter pylori in gastric carcinogenesis. Gastroenterol Clin North Am 2002;31:517-35.
36. Okoh V, Deoraj A, Roy D. Estrogen-induced reactive oxygen species-mediated signaling contributeto breast cancer. Biochim Biophys Acta 2011;1815:115\-33.
37. Available from: www.ensembl.org. [cited 2012 Jul 25.]
38. Lee PH, Shatkay H. F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res 2008;36: D820-4.
39. Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH, et al. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res 2007;9:R76.
40. Chua PJ, Lee EH, Yu Y, Yip GW, Tan PH, Bay BH. Silencing the Peroxiredoxin III gene inhibits cell proliferation in breast cancer. Int J Oncol 2010;36:359-64.
41. Bae JY, Ahn SJ, Han W, Noh DY. Peroxiredoxin I and II inhibit H2O2-induced cell death in MCF-7 cell lines. J Cell Biochem 2007;101: 1038-45.
42. Noh YH, Baek JY, Jeong W, Rhee SG, Chang TS. Sulfiredoxin trans-location into mitochondria plays a crucial role in reducing hyperox-idized Peroxiredoxin III. J Biol Chem 2009;284:8470-7.
43. Shin DH, Park HM, Jung KA, Choi HG, Kim JA, Kim DD, et al. The NRF2-heme oxygenase-1 system modulatescyclosporine A-induced epithelial-mesenchymal transition and renal fibrosis. Free Radic Biol Med 2010;48:1051-63.
44. Loignon M, Miao W, Hu L, Bier A, Bismar TA, Scrivens PJ, et al. Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy. Mol Cancer Ther 2009;8:2432-40.
45. Aritake N, Tamaki Y, Masuda N, Nakano Y, Monden T, Noguchi S, et al. High expression of two genes selected by i AFLP: a new prognostic factor of estrogen receptor-positive breast cancer. Oncol Rep 2004; 12:381-7.